Publications:

---

EML4-ALK biology and drug resistance in Non-Small Cell Lung Cancer: a new phase of discoveries.

Molecular Oncology

Elshatlawy, Mariam M; Sampson, Josephina J; Clarke, Katy K; Bayliss, Richard R

Publication Date: 2023-05-07

Variant appearance in text: ALK: L1152P

PubMed Link: 37149843

Variant Present in the following documents:

• Main text
• MOL2-17-950.pdf

View BVdb publication page

---

Molecular Anatomy of the EML4-ALK Fusion Protein for the Development of Novel Anticancer Drugs.

International Journal Of Molecular Sciences

Cheon, So Yeong SY; Kwon, Sunghark S

Publication Date: 2023-03-18

Variant appearance in text: ALK: L1152P

PubMed Link: 36982897

Variant Present in the following documents:

• Main text
• ijms-24-05821.pdf

View BVdb publication page

---

Non-Small Cell Lung Cancer Targeted Therapy: Drugs and Mechanisms of Drug Resistance.

International Journal Of Molecular Sciences

Wu, Jiajia J; Lin, Zhenghong Z

Publication Date: 2022-12-01

Variant appearance in text: ALK: L1152P

PubMed Link: 36499382

Variant Present in the following documents:

• Main text
• ijms-23-15056.pdf

View BVdb publication page

---

Case report: BRAF A598-T599insV mutation as a potential resistance mechanism to alectinib in ALK-rearranged lung adenocarcinoma.

Frontiers In Oncology

Pasau, Thomas T; Wauters, Els E; Wauters, Isabelle I; Duplaquet, Fabrice F; Pirard, Lionel L; Pop-Stanciu, Claudia C; D'Haene, Nicky N; Dupont, Michael M; Vander Borght, Thierry T; Rondelet, Benoît B; Ocak, Sebahat S

Publication Date: 2022

Variant appearance in text: ALK: L1152P

PubMed Link: 36419902

Variant Present in the following documents:

• Main text
• fonc-12-985446.pdf

View BVdb publication page

---

The Landscape of ALK-Rearranged Non-Small Cell Lung Cancer: A Comprehensive Review of Clinicopathologic, Genomic Characteristics, and Therapeutic Perspectives.

Cancers

Cognigni, Valeria V; Pecci, Federica F; Lupi, Alessio A; Pinterpe, Giada G; De Filippis, Chiara C; Felicetti, Cristiano C; Cantini, Luca L; Berardi, Rossana R

Publication Date: 2022-09-29

Variant appearance in text: ALK: L1152P

PubMed Link: 36230686

Variant Present in the following documents:

• Main text
• cancers-14-04765.pdf

View BVdb publication page

---

Molecular targeted therapy for anticancer treatment.

Experimental & Molecular Medicine

Min, Hye-Young HY; Lee, Ho-Young HY

Publication Date: 2022-10

Variant appearance in text: ALK: L1152P

PubMed Link: 36224343

Variant Present in the following documents:

• Main text
• 12276_2022_Article_864.pdf

View BVdb publication page

---

Small-molecule inhibitors, immune checkpoint inhibitors, and more: FDA-approved novel therapeutic drugs for solid tumors from 1991 to 2021.

Journal Of Hematology & Oncology

Wu, Qing Q; Qian, Wei W; Sun, Xiaoli X; Jiang, Shaojie S

Publication Date: 2022-10-08

Variant appearance in text: ALK: L1152P

PubMed Link: 36209184

Variant Present in the following documents:

• Main text
• 13045_2022_Article_1362.pdf

View BVdb publication page

---

Durable clinical response to ALK tyrosine kinase inhibitors in ALK-rearranged non-small cell lung cancer: a case report.

Translational Cancer Research

Hu, Han H; Dai, Hui H; Ding, Liren L

Publication Date: 2022-08

Variant appearance in text: ALK: L1152P

PubMed Link: 36093526

Variant Present in the following documents:

• Main text
• tcr-11-08-2967.pdf

View BVdb publication page

---

Holistic View of ALK TKI Resistance in ALK-Positive Anaplastic Large Cell Lymphoma.

Frontiers In Oncology

Wang, Yuan Y; He, Jing J; Xu, Manyu M; Xue, Qingfeng Q; Zhu, Cindy C; Liu, Juan J; Zhang, Yaping Y; Shi, Wenyu W

Publication Date: 2022

Variant appearance in text: ALK: L1152P

PubMed Link: 35211406

Variant Present in the following documents:

• Main text
• fonc-12-815654.pdf

View BVdb publication page

---

Final efficacy and safety data, and exploratory molecular profiling from the phase III ALUR study of alectinib versus chemotherapy in crizotinib-pretreated ALK-positive non-small-cell lung cancer.

Esmo Open

Wolf, J J; Helland, Å Å; Oh, I-J IJ; Migliorino, M R MR; Dziadziuszko, R R; Wrona, A A; de Castro, J J; Mazieres, J J; Griesinger, F F; Chlistalla, M M; Cardona, A A; Ruf, T T; Trunzer, K K; Smoljanovic, V V; Novello, S S

Publication Date: 2022-01-15

Variant appearance in text: ALK: L1152P

PubMed Link: 35042152

Variant Present in the following documents:

• Main text
• main.pdf

View BVdb publication page

---

Final efficacy and safety data, and exploratory molecular profiling from the phase III ALUR study of alectinib versus chemotherapy in crizotinib-pretreated ALK-positive non-small-cell lung cancer.

Esmo Open

Wolf, J J; Helland, Å Å; Oh, I-J IJ; Migliorino, M R MR; Dziadziuszko, R R; Wrona, A A; de Castro, J J; Mazieres, J J; Griesinger, F F; Chlistalla, M M; Cardona, A A; Ruf, T T; Trunzer, K K; Smoljanovic, V V; Novello, S S

Publication Date: 2022-02

Variant appearance in text: ALK: L1152P

PubMed Link: 35042152

Variant Present in the following documents:

• Main text
• main.pdf

View BVdb publication page

---

Utility of the Ba/F3 cell system for exploring on-target mechanisms of resistance to targeted therapies for lung cancer.

Cancer Science

Koga, Takamasa T; Suda, Kenichi K; Mitsudomi, Tetsuya T

Publication Date: 2022-03

Variant appearance in text: ALK: L1152P

PubMed Link: 34997674

Variant Present in the following documents:

• CAS-113-815-s001.pdf

View BVdb publication page

---

Resistance to Targeted Agents Used to Treat Paediatric ALK-Positive ALCL.

Cancers

Hare, Lucy L; Burke, G A Amos GAA; Turner, Suzanne D SD

Publication Date: 2021-11-29

Variant appearance in text: ALK: L1152P

PubMed Link: 34885113

Variant Present in the following documents:

• Main text
• cancers-13-06003.pdf

View BVdb publication page

---

Resistance to Targeted Agents Used to Treat Paediatric ALK-Positive ALCL.

Cancers

Hare, Lucy L; Burke, G A Amos GAA; Turner, Suzanne D SD

Publication Date: 2021-11-29

Variant appearance in text: ALK: L1152P

PubMed Link: 34885113

Variant Present in the following documents:

• Main text
• cancers-13-06003.pdf

View BVdb publication page

---

The Resistance Mechanisms and Treatment Strategies for ALK-Rearranged Non-Small Cell Lung Cancer.

Frontiers In Oncology

Pan, Yue Y; Deng, Chao C; Qiu, Zhenhua Z; Cao, Chenghui C; Wu, Fang F

Publication Date: 2021

Variant appearance in text: ALK: L1152P

PubMed Link: 34660278

Variant Present in the following documents:

• Main text
• fonc-11-713530.pdf

View BVdb publication page

---

Targeted Therapy of Papillary Thyroid Cancer: A Comprehensive Genomic Analysis.

Frontiers In Endocrinology

Hescheler, Daniel A DA; Riemann, Burkhard B; Hartmann, Milan J M MJM; Michel, Maximilian M; Faust, Michael M; Bruns, Christiane J CJ; Alakus, Hakan H; Chiapponi, Costanza C

Publication Date: 2021

Variant appearance in text: ALK: L1152P

PubMed Link: 34630336

Variant Present in the following documents:

• Table_1.xlsx, sheet 2

View BVdb publication page

---

Will the clinical development of 4th-generation "double mutant active" ALK TKIs (TPX-0131 and NVL-655) change the future treatment paradigm of ALK+ NSCLC?

Translational Oncology

Ou, Sai-Hong Ignatius SI; Nagasaka, Misako M; Brazel, Danielle D; Hou, Yujie Y; Zhu, Viola W VW

Publication Date: 2021-11

Variant appearance in text: ALK: L1152P

PubMed Link: 34365220

Variant Present in the following documents:

• Main text
• main.pdf

View BVdb publication page

---

One-Step Polymerase Chain Reaction-Free Nanowire-Based Plasma Cell-Free DNA Assay to Detect EML4-ALK Fusion and to Monitor Resistance in Lung Cancer.

The Oncologist

Lee, Youngjoo Y; Cho, Youngnam Y; Park, Eun Young EY; Park, Seong-Yun SY; Hwang, Kum Hui KH; Han, Ji-Youn JY

Publication Date: 2021-10

Variant appearance in text: ALK: L1152P

PubMed Link: 34272914

Variant Present in the following documents:

• ONCO-26-e1683-s002.pdf

View BVdb publication page

---

Exceptional response to the ALK and ROS1 inhibitor lorlatinib and subsequent mechanism of resistance in relapsed ALK F1174L-mutated neuroblastoma.

Cold Spring Harbor Molecular Case Studies

Liu, Tingting T; Merguerian, Matthew D MD; Rowe, Steven P SP; Pratilas, Christine A CA; Chen, Allen R AR; Ladle, Brian H BH

Publication Date: 2021-08

Variant appearance in text: ALK: L1152P

PubMed Link: 34210658

Variant Present in the following documents:

• Main text
• MCS006064Liu.pdf

View BVdb publication page

---

TPX-0131, a Potent CNS-penetrant, Next-generation Inhibitor of Wild-type ALK and ALK-resistant Mutations.

Molecular Cancer Therapeutics

Murray, Brion W BW; Zhai, Dayong D; Deng, Wei W; Zhang, Xin X; Ung, Jane J; Nguyen, Vivian V; Zhang, Han H; Barrera, Maria M; Parra, Ana A; Cowell, Jessica J; Lee, Dong J DJ; Aloysius, Herve H; Rogers, Evan E

Publication Date: 2021-09

Variant appearance in text: ALK: L1152P

PubMed Link: 34158340

Variant Present in the following documents:

• Main text
• 1499.pdf

View BVdb publication page

---

Current Knowledge about Mechanisms of Drug Resistance against ALK Inhibitors in Non-Small Cell Lung Cancer.

Cancers

Smolle, Elisabeth E; Taucher, Valentin V; Lindenmann, Joerg J; Jost, Philipp J PJ; Pichler, Martin M

Publication Date: 2021-02-09

Variant appearance in text: ALK: L1152P

PubMed Link: 33572278

Variant Present in the following documents:

• Main text
• cancers-13-00699.pdf

View BVdb publication page

---

Resistance to anaplastic lymphoma kinase inhibitors: knowing the enemy is half the battle won.

Translational Lung Cancer Research

Tabbò, Fabrizio F; Reale, Maria Lucia ML; Bironzo, Paolo P; Scagliotti, Giorgio V GV

Publication Date: 2020-12

Variant appearance in text: ALK: L1152P

PubMed Link: 33489817

Variant Present in the following documents:

• Main text
• tlcr-09-06-2545.pdf

View BVdb publication page

---

The Emerging Therapeutic Landscape of ALK Inhibitors in Non-Small Cell Lung Cancer.

Pharmaceuticals (Basel, Switzerland)

Gristina, Valerio V; La Mantia, Maria M; Iacono, Federica F; Galvano, Antonio A; Russo, Antonio A; Bazan, Viviana V

Publication Date: 2020-12-18

Variant appearance in text: ALK: L1152P

PubMed Link: 33352844

Variant Present in the following documents:

• Main text
• pharmaceuticals-13-00474.pdf

View BVdb publication page

---

Optimal Care for Patients with Anaplastic Lymphoma Kinase (ALK)-Positive Non-Small Cell Lung Cancer: A Review on the Role and Utility of ALK Inhibitors.

Cancer Management And Research

Singh, Abhay A; Chen, Hongbin H

Publication Date: 2020

Variant appearance in text: ALK: L1152P

PubMed Link: 32821158

Variant Present in the following documents:

• Main text
• cmar-12-6615.pdf

View BVdb publication page

---

Identification of targeted therapy options for gastric adenocarcinoma by comprehensive analysis of genomic data.

Gastric Cancer : Official Journal Of The International Gastric Cancer Association And The Japanese Gastric Cancer Association

Hescheler, Daniel A DA; Plum, Patrick S PS; Zander, Thomas T; Quaas, Alexander A; Korenkov, Michael M; Gassa, Asmae A; Michel, Maximilian M; Bruns, Christiane J CJ; Alakus, Hakan H

Publication Date: 2020-07

Variant appearance in text: ALK: L1152P

PubMed Link: 32107691

Variant Present in the following documents:

• 10120_2020_1045_MOESM1_ESM.xlsx, sheet 12

View BVdb publication page

---

A case of primary pulmonary atypical carcinoid with EML4-ALK rearrangement.

Cancer Biology & Therapy

Liu, Na N; Wang, Jingjing J; Fu, Xiao X; Zheng, Xiaoqiang X; Gao, Huan H; Tian, Tao T; Ruan, Zhiping Z; Yao, Yu Y

Publication Date: 2020

Variant appearance in text: ALK: L1152P

PubMed Link: 31559892

Variant Present in the following documents:

• Main text

View BVdb publication page

---

Profile of alectinib for the treatment of ALK-positive non-small cell lung cancer (NSCLC): patient selection and perspectives.

Oncotargets And Therapy

Karachaliou, Niki N; Fernandez Bruno, Manuel M; Bracht, Jillian Wilhelmina Paulina JWP; Rosell, Rafael R

Publication Date: 2019

Variant appearance in text: ALK: L1152P

PubMed Link: 31354290

Variant Present in the following documents:

• Main text
• ott-12-4567.pdf

View BVdb publication page

---

Targeting anaplastic lymphoma kinase in neuroblastoma.

Apmis : Acta Pathologica, Microbiologica, Et Immunologica Scandinavica

Umapathy, Ganesh G; Mendoza-Garcia, Patricia P; Hallberg, Bengt B; Palmer, Ruth H RH

Publication Date: 2019-05

Variant appearance in text: ALK: L1152P

PubMed Link: 30803032

Variant Present in the following documents:

• Main text
• APM-127-288.pdf

View BVdb publication page

---

Circulating tumor cells (CTCs) for the noninvasive monitoring and personalization of non-small cell lung cancer (NSCLC) therapies.

Journal Of Thoracic Disease

Pawlikowska, Patrycja P; Faugeroux, Vincent V; Oulhen, Marianne M; Aberlenc, Agathe A; Tayoun, Tala T; Pailler, Emma E; Farace, Françoise F

Publication Date: 2019-01

Variant appearance in text: ALK: L1152P

PubMed Link: 30775027

Variant Present in the following documents:

• Main text

View BVdb publication page

---

(J)ALEX the great: a new era in the world of ALK inhibitors.

Journal Of Thoracic Disease

Brosseau, Solenn S; Gounant, Valérie V; Zalcman, Gérard G

Publication Date: 2018-07

Variant appearance in text: ALK: L1152P

PubMed Link: 30123543

Variant Present in the following documents:

• Main text

View BVdb publication page

---

Structure and energy based quantitative missense variant effect analysis provides insights into drug resistance mechanisms of anaplastic lymphoma kinase mutations.

Scientific Reports

Li, Jianzong J; Huang, Yue Y; Wu, Miaomiao M; Wu, Chuanfang C; Li, Xin X; Bao, Jinku J

Publication Date: 2018-07-13

Variant appearance in text: ALK: L1152P

PubMed Link: 30006516

Variant Present in the following documents:

• Main text
• 41598_2018_28752_MOESM3_ESM.xlsx, sheet 1
• 41598_2018_28752_MOESM5_ESM.xlsx, sheet 1
• 41598_2018_Article_28752.pdf
• 41598_2018_28752_MOESM7_ESM.xlsx, sheet 1

View BVdb publication page

---

Treating ALK-positive non-small cell lung cancer.

Annals Of Translational Medicine

Ziogas, Dimitrios C DC; Tsiara, Anna A; Tsironis, Georgios G; Lykka, Maria M; Liontos, Michalis M; Bamias, Aristotelis A; Dimopoulos, Meletios-Athanasios MA

Publication Date: 2018-04

Variant appearance in text: ALK: L1152p

PubMed Link: 29862230

Variant Present in the following documents:

• Main text

View BVdb publication page

---

Formalin fixation increases deamination mutation signature but should not lead to false positive mutations in clinical practice.

Plos One

Prentice, Leah M LM; Miller, Ruth R RR; Knaggs, Jeff J; Mazloomian, Alborz A; Aguirre Hernandez, Rosalia R; Franchini, Patrick P; Parsa, Kourosh K; Tessier-Cloutier, Basile B; Lapuk, Anna A; Huntsman, David D; Schaeffer, David F DF; Sheffield, Brandon S BS

Publication Date: 2018

Variant appearance in text: ALK: L1152P

PubMed Link: 29698444

Variant Present in the following documents:

• pone.0196434.s001.xlsx, sheet 3
• pone.0196434.s001.xlsx, sheet 2
• pone.0196434.s001.xlsx, sheet 1

View BVdb publication page

---

Tumor Resistance against ALK Targeted Therapy-Where It Comes From and Where It Goes.

Cancers

Sharma, Geeta Geeta GG; Mota, Ines I; Mologni, Luca L; Patrucco, Enrico E; Gambacorti-Passerini, Carlo C; Chiarle, Roberto R

Publication Date: 2018-02-28

Variant appearance in text: ALK: L1152P

PubMed Link: 29495603

Variant Present in the following documents:

• Main text
• cancers-10-00062.pdf

View BVdb publication page

---

Does ALK-rearrangement predict favorable response to the therapy of bevacizumab plus pemetrexed in advanced non-small-cell lung cancer? Case report and literature review.

Clinical And Translational Medicine

Liu, Zhichao Z; Bao, Youting Y; Li, Butuo B; Sun, Xindong X; Wang, Linlin L

Publication Date: 2018-01-09

Variant appearance in text: ALK: L1152P

PubMed Link: 29318404

Variant Present in the following documents:

• Main text
• 40169_2017_Article_178.pdf

View BVdb publication page

---